scispace - formally typeset
L

Lisa Goers

Researcher at Harvard University

Publications -  10
Citations -  836

Lisa Goers is an academic researcher from Harvard University. The author has contributed to research in topics: Shigella & Effector. The author has an hindex of 5, co-authored 8 publications receiving 541 citations. Previous affiliations of Lisa Goers include Broad Institute & Imperial College London.

Papers
More filters
Journal ArticleDOI

Co-culture systems and technologies: taking synthetic biology to the next level.

TL;DR: An overview of existing experimental and theoretical co-culture set-ups in synthetic biology and adjacent fields is given here, and challenges and opportunities involved in such experiments are discussed.
Journal ArticleDOI

Functional degradation: A mechanism of NLRP1 inflammasome activation by diverse pathogen enzymes

TL;DR: A distinct mechanism of pathogen-sensing mediated by an immune sensor protein called NLRP1B, a member of the nucleotide-binding domain leucine-rich repeat (NLRP) protein superfamily, is described, which finds that N-terminal cleavage of NL RP1B by LF protease results in destabilization of NLRP 1B and its degradation by the proteasome.
Journal ArticleDOI

NAIP-NLRC4-deficient mice are susceptible to shigellosis

TL;DR: It is demonstrated that intestinal epithelial cell (IEC)-specific NAIP–NLRC4 activity is sufficient to protect mice from shigellosis, and the results suggest that the lack of an inflammasome response in IECs may help explain the susceptibility of humans to Shigella.
Journal ArticleDOI

Whole-cell Escherichia coli lactate biosensor for monitoring mammalian cell cultures during biopharmaceutical production

TL;DR: A whole‐cell Escherichia coli lactate biosensor based on the lldPRD operon is developed and successfully used to monitor lactate concentration in mammalian cell cultures and serves as a blueprint for how to capitalize on the wealth of genetic operons for metabolite sensing available in nature for the development of other whole-cell biosensors.
Journal ArticleDOI

Emerging strategies for engineering Escherichia coli Nissle 1917-based therapeutics.

TL;DR: In this article , the authors summarize the latest progress in rationally engineered variants of Escherichia coli Nissle 1917 (EcN) for the treatment of infectious diseases, metabolic disorders, and inflammatory bowel diseases.